Company: QXO-PB
Filing Date: 2025-02-12
Form Type: DFAN14A
Source: 0001140361-25-003963
Chunk: 0

Company: QXO, Inc.
Filing Date: 2025-02-12
Form: DFAN14A
Chunk 0
---
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549 SCHEDULE 14A
Proxy Statement Pursuant to Section 14(a) of the
Securities Exchange Act of 1934 Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box:

| ☐ | Preliminary Proxy Statement |

| ☐ | Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |

| ☐ | Definitive Proxy Statement |

| ☐ | Definitive Additional Materials |

| ☒ | Soliciting Material under § 240.14a-12 |

BEACON ROOFING SUPPLY, INC.
(Name of Registrant as Specified In Its Charter) QXO, INC.
BRAD JACOBS
IHSAN ESSAID
MATT FASSLER
MARK MANDUCA
(Name of Person(s) Filing Proxy Statement if other than the Registrant) Payment of Filing Fee (Check the appropriate box):

| ☒ | No fee required. |

| ☐ | Fee paid previously with preliminary materials. |

| ☐ | Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11. |

On February 12, 2025, QXO, Inc. issued the following press release: QXO Receives Antitrust Clearance for Acquisition of Beacon Roofing Supply Calls on Beacon to Remove Shareholder-Unfriendly Poison Pill GREENWICH, Conn., February 12, 2025 – QXO, Inc. (NYSE: QXO) announced today that it has obtained antitrust clearance in both the U.S. and Canada for its acquisition of Beacon Roofing Supply, Inc. (Nasdaq: BECN), paving the way for QXO to close the transaction quickly. The company confirmed that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act has expired and that it has received early termination of the waiting period from the Canadian Competition Bureau. “With committed financing in place and these necessary regulatory approvals secured, QXO is prepared to complete this acquisition and deliver immediate, compelling value to Beacon shareholders,” said Brad Jacobs, chairman and chief executive officer of QXO. “Beacon should remove its shareholder-unfriendly poison pill so shareholders can benefit from our premium all-c